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Purpose: Non-small cell lung cancers (NSCLC) are a heterogeneous group of carcinomas
harboring a variety of different gene mutations. We have utilized two distinct genetically
engineered mouse models of human NSCLC (adenocarcinoma) to investigate how genetic
factors within tumor parenchymal cells influence the in vivo tumor growth delay after one
or two fractions of radiation therapy (RT).
Materials and Methods: Primary lung adenocarcinomas were generated in vivo in mice by
intranasal delivery of an adenovirus expressing Cre-recombinase. Lung cancers expressed
oncogenic KrasG12D and were also deficient in one of two tumor suppressor genes: p53 or
Ink4a/ARF. Mice received no radiation treatment or whole lung irradiation in a single frac-
tion (11.6 Gy) or in two 7.3 Gy fractions (14.6 Gy total) separated by 24 h. In each case, the
biologically effective dose (BED) equaled 25 Gy10. Response to RT was assessed by micro-
CT 2 weeks after treatment. Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR) and immunohistochemical staining were performed to assess the integrity of
the p53 pathway, the G1 cell-cycle checkpoint, and apoptosis.
Results: Tumor growth rates prior to RT were similar for the two genetic variants of lung
adenocarcinoma. Lung cancers with wild-type (WT) p53 (LSL-Kras; Ink4a/ARFFL/FL mice)
responded better to two daily fractions of 7.3 Gy compared to a single fraction of 11.6 Gy
(P =0.002). There was no statistically significant difference in the response of lung can-
cers deficient in p53 (LSL-Kras; p53FL/FL mice) to a single fraction (11.6 Gy) compared to
7.3 Gy×2 (P =0.23). Expression of the p53 target genes p21 and PUMA were higher and
bromodeoxyuridine uptake was lower after RT in tumors with WT p53.
Conclusion: Using an in vivo model of malignant lung cancer in mice, we demonstrate
that the response of primary lung cancers to one or two fractions of RT can be influenced
by specific gene mutations.
Keywords: tumor cell biology, genetically engineered mouse models, fractionation, p53
INTRODUCTION
A substantial body of clinical and radiobiological evidence sug-
gests that small doses of fractionated radiation therapy (RT), in
comparison with a single or a few high-dose treatments, may con-
fer a therapeutic ratio because non-tumor tissues are preferentially
spared (Hall and Giaccia, 2006). It is postulated that the radiobio-
logical behavior of tumors (and normal tissues) is reflected in the
α/β ratio that characterizes their radiation survival curves (Hall
and Giaccia, 2006). However, the α/β ratio of a tumor is an empir-
ically derived parameter and, therefore, the biological basis for
differential tumor response to fractionated RT is largely unknown.
Using isogenic derivatives of glioblastoma U87 cells (ATCC# HTB-
14), some investigators have determined that the wild-type (WT)
tumor suppressor gene p53 promotes radiosensitivity to fraction-
ated RT (Gupta et al., 1996; Haas-Kogan et al., 1996, 1999; Yount
et al., 1996, 1998) by maintaining the integrity of the cell-cycle G1-
checkpoint (independent of apoptosis). However, others found no
significant difference in clonogenic cell survival when comparing
glioblastoma cells with WT (U87 cells) or mutant p53 (T98 cells,
ATCC# CRL-1690) (Quick and Gewirtz, 2006). Non-small lung
cancer cell lines have also been evaluated for evidence of cell-cycle
synchronization following anti-cancer therapy prior to delivery of
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RT (Asaka-Amano et al., 2007). We wished to further investigate
the role of an intact G1 cell-cycle checkpoint on the response of
primary lung cancers in vivo to a single-dose or two fractions of
RT using two different mouse models of primary non-small cell
lung cancer (NSCLC).
A methodological approach for studying radiation biology
in vivo using primary lung cancers in mice has been previously
described (Kirsch et al., 2010a). Tumors in these genetically engi-
neered mouse models (GEMMs) bear close resemblance to human
tumors at the histological and genetic levels (Sweet-Cordero et al.,
2005) and develop in a native tumor microenvironment within an
immunocompetent mouse. Thus, these mouse models may have
significant advantages for studying mechanisms of tumor response
to RT. In addition to closely recapitulating human lung cancers
(Sharpless and Depinho, 2006), GEMMs provide the opportu-
nity to generate lung cancers harboring different gene mutations
that are relevant to human lung cancer. In the present work, we
utilize two distinct GEMMs of primary lung adenocarcinomas ini-
tiated by the conditional, Cre-mediated activation of oncogenic
KrasG12D (Jackson et al., 2001), and deletion of a tumor sup-
pressor gene, either p53 (Jackson et al., 2005) or Ink4ap16/ARFp19
(Aguirre et al., 2003). p53 and Ink4ap16/ARFp19 have been shown
to play critical roles in multiple cellular responses after exposure
to RT, including cell-cycle arrest, senescence, and apoptosis (Gud-
kov and Komarova, 2003). Furthermore, along with Kras, these
two tumor suppressor genes are known to be among the most
frequently mutated genes in human lung adenocarcinomas (Ding
et al., 2008). Using an in vivo approach, we describe differences
in primary lung tumor response to fractionated RT based on
mutations in p53 or Ink4a/ARF.
MATERIALS AND METHODS
The Duke Institutional Animal Care and Use Committee approved
all of the described protocols using vertebrate animals.
MOUSE BREEDING
All mice expressed a conditional Lox-Stop-Lox KrasG12D/+ (LSL-
Kras) allele (Jackson et al., 2001). Expression of oncogenic
KrasG12D is controlled by a Cre-regulatable transcriptional Stop
element. Because this conditional oncogenic Kras allele was tar-
geted into the endogenous locus (Tuveson et al., 2004), endoge-
nous levels of oncogenic KrasG12D protein are expressed following
removal of the stop element upon expression of Cre-recombinase.
LSL-Kras mice for this study were bred with mice with condi-
tional alleles for the tumor suppressors p53 (Jonkers et al., 2001)
or Ink4a/ARF (Aguirre et al., 2003). In these conditional alleles,
LoxP sites flank important coding regions in these tumor sup-
pressor genes and are termed floxed alleles: p53FL or Ink4a/ARFFL.
These conditional alleles are targeted to their respective endoge-
nous loci so that prior to deletion, expression of the respective WT
tumor suppressor gene is normal. However, in the presence of Cre-
recombinase the LoxP sites recombine, thereby creating a deletion
with loss of tumor suppressor gene function. Mice were bred to
contain one allele of the conditional oncogenic Kras gene while
simultaneously containing tumor suppressor genes p53 (LSL-Kras;
p53FL/FL) or Ink4a/ARF (LSL-Kras; Ink4a/ARFFL/FL) with both
alleles flanked by loxP sites.
INFECTION WITH ADENOVIRUS EXPRESSING Cre-RECOMBINASE
Adult mice expressing the conditional alleles described above were
infected with adenovirus expressing Cre-recombinase (Adeno-
Cre) intranasally as previously described (Kirsch et al., 2010a).
Adeno-Cre preferentially infects the lung epithelium and Cre-
recombinase acts on the conditional alleles, allowing the mice to
develop multiple lung tumors. Tumors become visible on micro-
CT, a non-invasive small animal imaging modality, approximately
60 days after Adeno-Cre infection.
TISSUE COLLECTION
In order to isolate lung tumors for gene expression and histo-
logic studies, mouse lungs along with other tissues including small
intestine, thymus, and spleen were collected at the time of sacri-
fice. For studies in which bromodeoxyuridine (BrdU) immuno-
histochemical staining was performed, mice were injected with
5 mg/mL of BrdU 2 h prior to sacrifice to allow for BrdU incor-
poration to take place. Tissue used for gene expression analysis
was stored in RNAlater (Ambion #AM-7021). Tissue utilized for
immunohistochemical analysis was placed in a histology cassette
in formalin overnight prior to paraffin embedding. Slides were
cut from paraffin embedded tissue to generate unstained slides for
immunohistochemical staining.
RNA ISOLATION AND qRT-PCR
RNA was isolated from tissue stored in RNAlater using a tradi-
tional organic solvent precipitation technique followed by RNA
cleanup using the RNeasy MinElute Cleanup kit (Qiagen #74204).
RNA 260/280 ratios were consistently better than 2.00 and 260/230
ratios were generally better than 1.50. After converting isolated
RNA to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad
#170-8890), TaqMan probes directed against p53, p21, and PUMA
were used to measure gene expression relative to the house-keeping
gene GAPDH using a real-time thermal cycler (Bio-RAD, DNA
Engine). Student’s t -test (two-tailed) was performed to compare
relative gene expression among different treatment cohorts.
IMMUNOHISTOCHEMISTRY
Immunohistochemical staining for BrdU (1:200, Becton Dick-
inson, Cat #3457580), phospho-histone H3 (1:200, Cell Signal-
ing, Cat#9701), and cleaved-caspase 3 (1:500, R&D Systems,
Cat#AF835) was performed on unstained slides cut from formalin-
fixed paraffin embedded tissue blocks according to standard
immunohistochemistry protocols. Hematoxylin counterstaining
was used for all immunohistochemical studies. Analysis of his-
tological specimens was performed by calculating the number
of positively staining cells/400× powered field within regions of
tumor for each slide. When possible, a two-tailed Student’s t -
test was performed to compare tumors among different treatment
cohorts.
RADIATION TREATMENT
Mice were placed in radiation treatment cradles with lead shield-
ing above and below the thorax to minimize normal tissue injury.
Single-dose radiation treatment was delivered using an X-RAD
320 biological irradiator (Precision X-Ray) at a dose output of
320 kV, 10 mA to deliver 11.6 Gy at a dose rate of 69 cGy/min. In
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the two-fraction arm of the study, radiation was delivered using
the same setup and dose rate with 24 h of separation between frac-
tions. To provide an estimate of equivalent dose, we calculated the
biologically effective dose (BED) (Fowler, 2010) in two fractions
for a single-dose of 11.6 Gy, we estimated that the α/β ratio for
lung cancer in mice was 10 and used the following formula for
BED or E/α (Fowler, 2006): BED= E/α= nd(1+ d/α/β), where E
is the log cell kill from n fractions of d grays.
Using an α/β ratio of 10 Gy, the BED for a single 11.6 Gy frac-
tion is 25 Gy10. Therefore, the dose required for each of the two
fractions to deliver 25 Gy10 would be 7.3 Gy. Animals that did not
receive any RT still underwent the stress of placement in the radi-
ation treatment cradles for the same length of time as mice that
underwent single-dose radiation treatment. Dose rate calibrations
were performed by the Duke University Office of Radiation Safety.
MICRO-CT IMAGING
Computed tomography techniques developed especially for small
animal imaging (Micro-CT) allowed us to perform this study. Mice
were imaged at 2-week intervals before and after radiation treat-
ment. We used a custom built micro-CT system that has been
previously described (Badea et al., 2008). Mice were anesthetized
using isoflurane and then were subsequently immobilized in a
cradle during CT image acquisition with isoflurane anesthesia
via a nose cone delivery system. Projections were acquired using
a single tube/detector over a circular orbit of 195˚ with a step
angle of 0.65˚. Reconstructions were performed using a commer-
cially available CT reconstruction program (COBRA Exxim, v5.0),
with a filtered back projection technique. A resolution of approx-
imately 88µ/pixel was achieved. The cumulative radiation dose
from all three micro-CT scans was 0.3 Gy, which represents about
2% from the 14.6 Gy treatment dose. Using this approach, we have
been able to achieve reasonably high-throughput imaging of up to
approximately 60 mice in a single day.
CALCULATING TUMOR VOLUMES AND GENERATING GROWTH CURVES
Following CT reconstruction, images were analyzed using an
advanced image analysis software suite (Visage Imaging, Amira
v5.0). Tumor volumes were calculated by contouring individual
tumor areas on each slice of the reconstructed CT scans. In most
cases, multiple tumors were contoured for each mouse. The indi-
vidual assigned to contouring tumor volumes was blinded to the
experiment and therefore not aware of mouse genotype or treat-
ment regimen at the time of contouring. Tumors were followed
over time before and after radiation treatment and tumor growth
rate was determined relative to initial tumor volume calculations.
GraphPad Prism software (v5.02) was utilized to perform linear
regression and fit growth curves based on tumor volumes from
each cohort (LSL-Kras; p53FL/FL orLSL-Kras; Ink4a/ARFFL/FL) with
0, 1, and 2 radiation treatments. Student’s t -tests were used to
analyze differences in relative growth at 14 days after radiation
treatment within each mouse genotype.
RESULTS
IN VIVO ASSESSMENT OF PRIMARY LUNG CANCER GROWTH USING
MICRO-CT
Intranasal delivery of Adeno-Cre into LSL-Kras; p53FL/FL or LSL-
Kras; Ink4a/ARFFL/FL mice led to the development of multiple,
aggressive adenocarcinomas in the lungs bilaterally. Primary lung
cancers in mice were generated and imaged with micro-CT as
previously described (Kirsch et al., 2010a). The mice were imaged
with a thoracic micro-CT at 8 weeks after infection (baseline scan),
at 10 weeks (1 day before whole lung RT), and at 12 weeks (to
assess treatment response) (Figure 1). Lung tumors from both
genotypes were histologically similar to previously characterized
mouse tumors that are known to resemble human lung adeno-
carcinomas (Calbo et al., 2005) (Figures 2A,B). We used real-time
quantitative RT-PCR to confirm that primary tumors excised from
lungs of LSL-Kras; Ink4a/ARFFL/FL mice (Figure 2C – blue bar)
express p53, while tumors from LSL-Kras; p53FL/FL mice do not
(P = 0.0001, Figure 2C – red bar). Residual p53 expression in
the LSL-Kras; p53FL/FL tumors is likely from non-epithelial stro-
mal cells or possibly from epithelial cells with an unrecombined
p53FL allele (Jackson et al., 2005). Tumor growth rates from both
genotypes in the absence of RT (Figure 2D) were similar and the
volume doubling time of about 14 days (Figure 2E) was similar to
previous reports (Kirsch et al., 2010a; Oliver et al., 2010).
TUMOR RESPONSE TO ONE OR TWO FRACTIONS OF RT IN LUNG
CANCERS WITH DELETION OF p53 OR Ink4A/Arf
The bar graphs depicted in Figures 3A,B show relative volume
increase over two time points: time= 0 days (relative tumor vol-
ume at the time of RT, 10 weeks after Adeno-Cre infection), and
time= 14 days (relative tumor volume 14 days after RT, 12 weeks
after Adeno-Cre infection). Relative tumor volume was assessed
by normalizing the tumor volume at 14 days after RT to the
tumor volume at the time of RT. Lung cancers in LSL-Kras;
Ink4a/ARFFL/FL mice that received a single fraction of 11.6 Gy
had decreased growth compared to unirradiated tumors [factor
of 1.53 (SEM – 0.03), n= 26 tumors vs. factor of 2.19 (SEM –
0.03), n= 27 tumors, P = 0.003], but two fractions of 7.3 Gy led
to an even better response [factor of 0.88 (SEM – 0.01), n= 14
tumors,P = 0.002, Figure 3A]. Although lung cancers inLSL-Kras;
p53FL/FL mice also responded well to two fractions of 7.3 Gy [fac-
tor of 0.96 (SEM – 0.04), n= 14 tumors], this was not statistically
different than the response to a single fraction of 11.6 Gy (fac-
tor of 1.2, n= 28 tumors, P = 0.23, Figure 3B). Therefore, these
results suggest that lung cancers respond differently to one vs. two
fractions of RT depending on the genotype of the lung cancer.
INTERROGATING THE p53 PATHWAY
To investigate how p53-mediated signaling influences the radia-
tion response of lung tumors, we examined the mRNA expres-
sion of p53 targets, which regulate p53-mediated cell-cycle arrest
and apoptosis, in lung tumors after a single fraction of 11.6 Gy
whole lung RT. Primary tumors of each genotype were excised
from the lungs 4 h after RT, and the mRNA levels of p53 tran-
scriptional targets p21 and PUMA were measured by quan-
titative reverse transcription-polymerase chain reaction (qRT-
PCR). In tumors with WT p53 (LSL-Kras; Ink4a/ARFFL/FL) a
nearly 20-fold increase in p21 mRNA levels was noted after
RT (P = 0.003, Figure 4A – blue bars). Tumors from LSL-Kras;
p53FL/FL mice showed significantly lower levels of p21 activation
after RT (P = 0.09, Figure 4A – red bars). Similarly, RT-induced
PUMA mRNA expression was robust in tumors from LSL-Kras;
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FIGURE 1 | Experimental design schematic. (A) At around 42 days of age,
mice with differing genotypes are infected with an adenovirus expressing
Cre-recombinase (Adeno-Cre) via intranasal inhalation. Eight weeks after
infection mice develop tumors large enough to be visible by micro-CT
imaging. Mice are imaged again at 10 weeks after Adeno-Cre infection to
ensure appropriate identification of tumors with growth kinetics suggestive
of lung adenocarcinoma. Immediately after a second micro-CT scan, mice
undergo whole thorax irradiation with differing treatment regimens. Two
weeks after radiation treatment mice are imaged again to evaluate tumor
growth delay following radiation treatment. [(B) Top Panel] Image of custom
built Micro-CT scanner developed at the Duke Center for In vivo Microscopy
with isotropic resolution of 88µ. [(B) Bottom Panel] Reconstructed image
series were utilized to contour tumors to calculate gross tumor volumes
and monitor relative growth kinetics. SC, spinal cord; H, heart.
Ink4a/ARFFL/FL mice, but not in tumors from LSL-Kras; p53FL/FL
mice (P = 0.0001, Figure 4B – blue bars). Thus, these data indi-
cate that p53-mediated DNA damage response is significantly
more active in LSL-Kras; Ink4a/ARFFL/FL tumors as compared with
LSL-Kras; p53FL/FL tumors.
Because the induction of cyclin-dependent kinase inhibitor p21
contributes to the G1 cell-cycle arrest after irradiation (Kastan
and Bartek, 2004), we evaluated the progression of cell-cycle after
RT in the tumors from LSL-Kras; Ink4a/ARFFL/FL and LSL-Kras;
p53FL/FL mice by the labeling index of BrdU, which is a thymidine
analog that is incorporated into replicating DNA. Immunostain-
ing of the lungs with an antibody against BrdU (Figure 5) revealed
that tumors from LSL-Kras; Ink4a/ARFFL/FL mice had significantly
decreased BrdU uptake 4 h after RT (P = 0.005, Figure 5A), as
compared with unirradiated tumors, indicating the presence of an
intact G1 cell-cycle checkpoint. Thus, lung cancers with an intact
p53-dependent induction of p21 appear to undergo a radiation-
induced G1 cell-cycle arrestin vivo. In contrast, lung tumors from
LSL-Kras; p53FL/FL mice incorporated high levels of BrdU after
irradiation, indicating that these tumors lacked an intact G1 cell-
cycle checkpoint (Figure 5A). Interestingly, immunohistochem-
ical staining for phospho-histone H3, which is present in cells
during mitosis, revealed a significant reduction in tumors from
both genotypes after RT (Figure 5B). Finally, cleaved-caspase 3
staining was performed to evaluate the extent of radiation-induced
apoptosis. At 4 h after RT, apoptosis was an uncommon event in
both tumor types (Figure 5C).Taken together, these assays pro-
vide functional data to demonstrate that only in primary lung
tumors from LSL-Kras; Ink4a/ARFFL/FL mice, which retain p53, is
the radiation-induced p53 response functionally intact.
DISCUSSION
In this study, we utilized genetically engineered mouse models of
lung cancer to study the treatment response of one vs. two fractions
of radiation in lung adenocarcinomas harboring different muta-
tions in tumor suppressor genes. We have shown that lung cancers
in LSL-Kras; Ink4a/ARFFL/FL mice maintain the ability to induce
the p53 transcriptional target p21 and to activate the G1 cell-cycle
arrest. In contrast, we find that lung cancers in LSL-Kras; p53FL/FL
mice, which lack WT p53, have an impaired induction of p21 after
irradiation and fail to induce a G1 cell-cycle arrest. Our inability to
appreciate radiation-induced pre-mitotic apoptosis in the tumor
cells 4 h after RT in either of the two mouse models of lung cancer
may be because NSCLC tumors, like many other carcinomas, do
not respond to radiation damage with a robust apoptotic response
(Gudkov and Komarova, 2003). This factor is likely the reason
for a lack of p53 mediated radiation-induced apoptosis in either
of the two tumor types. Alternatively, it is also possible that the
time point (4 h after RT) we chose in this study is not appropriate
to detect cell death in these tumors after radiation. Lung cancers
with intact p53 inLSL-Kras; Ink4a/ARFFL/FL mice had an improved
response to two fractions of 7.3 Gy vs. a single fraction of 11.6 Gy.
In contrast, lung cancers lacking p53 in LSL-Kras; p53FL/FL mice
did not have a statistically significant difference in the response
to these two treatment regimens. These results suggest that tumor
genotype can affect the radiation response of primary cancers to
one vs. two fractions of RT.
This study has some limitations in recapitulating the treatment
of human lung cancer with RT. With inhalation of Adeno-Cre,
multiple tumors develop in a single mouse, which is not common
in patients diagnosed with NSCLC. We also utilized whole lung
RT, which may impact tumor growth differently than the rela-
tively small volume RT fields used in the clinic to treat lung cancer.
Additionally, fraction sizes of 7.3 and 11.6 Gy are not standard
doses used to treat human lung cancer. Finally, while tumorigene-
sis was initiated by recombination to activate LSL-Kras and delete
both alleles of either p53 of Ink4a/ARF, it is possible that some
tumors did not undergo all recombination events. In addition, it
is likely that the tumors developed additional random oncogenic
mutations as they grow means heterogeneity exists in each of the
cohorts.
Our experimental approach cannot differentiate whether dif-
ferences in radiation response between the two cohorts is due
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FIGURE 2 | Lung cancers from mice with conditional mutations in
LSL-Kras; Ink4a/ARFFL/FL and LSL-Kras; p53FL/FL have different levels of
p53 expression, but similar growth rates. Hematoxylin and eosin
stained slides of the lung (200×) demonstrate histologically similar
adenocarcinomas in (A) LSL-Kras; Ink4a/ARFFL/FL and (B) LSL-Kras; p53FL/FL
mice. (C) Quantitative RT-PCR shows significantly different levels of p53
expression in lung cancers from LSL-Kras; Ink4a/ARFFL/FL mice (n=11
tumors) when compared to LSL-Kras; p53FL/FL mice (n=11 tumors,
P <0.0001). (D) Relative tumor growth over time with no treatment
demonstrates similar growth rates in each tumor cohort at 56, 70, and
84 days following intranasal Adeno-Cre infection. Blue – lung cancers
(n=27) from LSL-Kras; Ink4a/ARFFL/FL mice, Red – lung cancers (n=45)
from LSL-Kras; p53FL/FL mice. (E) Serially reconstructed Micro-CT scans at
56, 70, and 84 days after Adeno-Cre infection from a LSL-Kras; p53FL/FL
mouse documents clear and measurable tumor growth over time. T,
tumor; H, heart. Error bars – SEM.
to loss of p53 function in the LSL-Kras; p53FL/FL tumors, loss
of Ink4A/Arf in the LSL-Kras; Ink4a/ARFFL/FL tumors, or a
contribution of the presence or absence of both gene muta-
tions. Because the genetic backgrounds of the LSL-Kras; p53FL/FL
and LSL-Kras; Ink4a/ARFFL/FL mice are not the same, we have
not made a direct comparison of tumor response for each
treatment across the two genotypes. However, the data from
Figure 3 suggests that lung cancers from both genotypes appear
to have a similar response to 7.3 Gy× 2, but there may be an
increased response of lung cancers in LSL-Kras; p53FL/FL mice
to a single-dose of 11.6 Gy. This could be one reason why
lung cancers in this genotype did not demonstrate a statistically
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FIGURE 3 | Quantification of relative tumor volume 14 days after a single
11.6 Gy fraction or two 7.3 Gy fraction radiation treatments. Lung cancers
in (A) LSL-Kras; Ink4a/ARFFL/FL and (B) LSL-Kras; p53FL/FL mice were imaged
prior to radiation therapy (Day 0) and 2 weeks after radiation therapy (Day 14).
Graphs show the average fold change for the lung tumors at 14 days.(A) Lung
cancers in LSL-Kras; Ink4a/ARFFL/FL mice show improved response to two
7.3 Gy fractions separated by 24 h compared to a single 11.6 Gy treatment as
measured by micro-CT at 14 days after radiation treatment (P =0.002). (B)
Lung cancers in LSL-Kras; p53FL/FL mice respond to a single 11.6 Gy fraction
and two 7.3 Gy fractions of radiation therapy with a small difference that is not
statistically significant as measured by micro-CT at 14 days after radiation
treatment (P =0.23). Error bars – SEM.
FIGURE 4 | Downstream p53 effectors, p21 and PUMA, are induced in
tumors with wild-type p53 expression following radiation therapy.
(A) Lung cancers from LSL-Kras; Ink4a/ARFFL/FL mice (blue bars, n=6 tumors:
no radiation, n=4 tumors: 11.6 Gy× 1) show significantly increased
expression of the cyclin-dependent kinase inhibitor, p21, 4 h after radiation
treatment, P =0.003. Lung cancers from LSL-Kras; p53FL/FL tumors (red bars,
n=4 tumors: no radiation, n=4 tumors: 11.6 Gy×1) show non-significant
modest increases in p21 expression following radiation treatment, P =0.09.
(B) Lung cancers from LSL-Kras; Ink4a/ARFFL/FL mice (blue bars, n=6 tumors:
no radiation, n= 4 tumors: 11.6 Gy×1) show significantly increased
expression of the p53 upregulated modulator of apoptosis, PUMA, 4 h after
radiation treatment, P =0.0001. Lung cancers from LSL-Kras; p53FL/FL tumors
(red bars, n=4 tumors: no radiation, n=4 tumors: 11.6 Gy×1) show
non-significant modest increases in PUMA expression following radiation
treatment, P =0.07. Activation of p21 and PUMA within the LSL-Kras; p53FL/FL
tumors may be due to p53 independent activation, non-recombined p53
alleles within the tumor cell population, or p53-dependent activation of
stromal cells isolated together with the tumor cells. Error bars – SEM.
significant different response to 11.6 Gy× 1 vs. 7.3 Gy× 2 treat-
ments.
Recently, we have demonstrated that certain normal tissues
lacking p53 have an increased sensitivity to radiation exposure.
For example, mice in which p53 is specifically deleted in gastroin-
testinal (GI) epithelial cells are sensitized to the radiation-induced
GI syndrome (Kirsch et al., 2010b). Others have also reported
that mice lacking p53 are sensitized to the radiation-induced
GI syndrome (Komarova et al., 2004; Leibowitz et al., 2011).
In addition, we have shown that mice lacking p53 specifically
in endothelial cells are sensitized to radiation-induced cardiac
injury (Lee et al., 2012). Because mice lacking p21 are also sen-
sitized to the radiation-induced GI syndrome and to radiation-
induced cardiac injury (Komarova et al., 2004; Kirsch et al.,
2010b; Leibowitz et al., 2011; Lee et al., 2012), it is conceiv-
able that lung cancers lacking p53 are less likely to respond to
fractionated RT as compared to a large single-dose of RT. This
difference in response may be due in part to a deficiency in
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FIGURE 5 | Immunohistochemistry of lung cancers shows an intact
radiation-induced G1 cell-cycle arrest in lung cancers from LSL-Kras;
Ink4a/ARFFL/FL mice, but not from LSL-Kras; p53FL/FL mice.
Immunohistochemistry of sections of lung from mice with lung cancer
with the indicated genotype was performed for: (A) Bromodeoxyuridine
(BrdU). (B) Phospho-Histone H3. (C) Cleaved-Caspase 3. Top Panels show
representative immunohistochemistry for lung tumors in LSL-Kras;
Ink4a/ARFFL/FL and LSL-Kras; p53FL/FL mice 4 h after radiation treatment with
11.6 Gy (200×, brown-antibody immunostaining, blue – hematoxylin).
Inserts show positive control staining for each antibody within unirradiated
(BrdU or phospho-histone H3) and irradiated (cleaved-caspase 3) thymus.
Bottom panels show quantification of immunohistochemical staining
which was performed by counting the number of positively stained
cells/random 400× powered field within the lung tumor parenchyma. All
analysis was done in a blinded fashion to treatment group and genotype.
Error bars – SEM.
the induction of p21 expression and activation of the G1 cell-
cycle checkpoint. Therefore, based on these results we hypothesize
that the p53 pathway and its ability to induce a G1 cell-cycle
arrest in tumor cells (Figure 5A) may play a role in the dif-
ferential response of lung cancers to one or two fractions of
RT.
We selected the two radiation regimens (11.6 Gy× 1 vs.
7.3 Gy× 2) based on a calculation for the BED and used a com-
monly acceptedα/β ratio of 10 Gy for lung cancer. The difference in
growth delay that we observed in lung cancers at 14 days between
the two regimens in the two genetic variants of the NSCLC raises
the intriguing possibility that the α/β ratio may not be equivalent
in the two mouse models of NSCLC. While more data points will
be required to formally define the α/β ratio in both mouse models
of lung cancer, we believe that such experiments have the potential
to provide a mechanistic basis at the genetic level for differences
in the α/β ratio.
In summary, we have investigated the impact of different gene
mutations in lung cancer on the response to one or two frac-
tions of radiation therapy using advanced mouse models of pri-
mary lung cancer. This system has advantages, albeit at a cost, to
traditional xenograft or even knockout mouse models. Tumors
form within the native tumor environment (lung parenchyma)
and tumor formation is temporally controlled by the initiation
of tumorigenesis with Adeno-Cre infection during adulthood.
Furthermore, expression of mutant alleles driving tumorigen-
esis occurs from the endogenous gene promoters at physio-
logic levels. Others have shown that such GEMMs of lung can-
cer may more faithfully predict the response of human lung
cancers to systemic therapy (Singh et al., 2010; Chen et al.,
2012). Therefore, we anticipate that these mouse models will
similarly be useful for investigating radiation biology (Kirsch,
2011).
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